Study on the Feelings of Euphoria Caused by Remimazolam During Gastroscopy and Colonoscopy and Their Related Factors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorZhangjie Yu
About this trial
This study aims to investigate the incidence of euphoria induced by remimazolam during gastrointestinal endoscopy and explore its related factors. Gastrointestinal endoscopy, a minimally invasive procedure, often causes discomfort and anxiety for patients. Remimazolam, a short-acting benzodiazepine, is increasingly used for sedation during these procedures due to its rapid onset, short metabolism, and controlled cardiorespiratory effects. This cross-sectional study will evaluate the effect of remimazolam on patient comfort, cooperation, and satisfaction during endoscopy, aiming to optimize sedation protocols and improve clinical outcomes.
Eligibility criteria
Qualifiers
Adults aged 18 to 65 years, regardless of gender.
Patients scheduled for routine painless gastrointestinal endoscopy, including gastroscopy, colonoscopy, or both.
ASA physical status classification: I or II.
BMI between 18 kg/m² and 28 kg/m².
Disqualifiers
History of psychiatric disorders such as schizophrenia, bipolar disorder, or personality disorders, or a history of alcohol, stimulant, or other substance abuse.
Known allergies or intolerance to any medication used in the study, including remimazolam, sufentanil, or benzodiazepines.
Patients requiring complex endoscopic procedures (e.g., ERCP, endoscopic submucosal dissection, endoscopic mucosal resection, or peroral endoscopic myotomy).
History of severe hepatic or renal disease.
Trial design
Treatments tested in this trial
- Remimazolam for Gastrointestinal Endoscopy Sedation
Treatment groups
305 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhangjie Yu
Lead sponsor
RenJi Hospital
Sponsor institution
Source ClinicalTrials.gov